LYSOZYME MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Lysozyme Market Size and Forecast – 2025 to 2032

The global lysozyme market is estimated to be valued at USD 605.9 Mn in 2025 and is expected to reach USD 992.2 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.3% from 2025 to 2032. This steady growth reflects increasing demand across pharmaceutical, food preservation, and healthcare sectors, driven by lysozyme’s antimicrobial properties and rising awareness of natural preservatives.

Key Takeaways of the Global Lysozyme Market

• Anti-infective therapies segment is projected to hold the largest share of the lysozyme market at 30.1% in 2025.
• Recombinant lysozyme segment is expected to account for 55.6% of the market share in 2025.
• Lysozyme solution segment is estimated to lead with 65.8% share in 2025.
• North America is expected to lead the market, holding a share of 39.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 24.6% in 2025.

Market Overview

Market trends indicate a growing preference for natural and bio-based additives, positioning lysozyme as a favorable alternative to synthetic preservatives. Innovations in biotechnology have enhanced production efficiency, reducing costs and expanding application areas. Additionally, rising investments in R&D, coupled with increasing consumer awareness about food safety and antimicrobial resistance, are expected to further propel the adoption of lysozyme in various industries over the coming years.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Lysozyme Market Insights, By Therapeutic Application – Anti-infective Therapies Segment Dominates due to Rising Antimicrobial Resistance and Strong Demand for Natural Bacteriolytic Solutions

The anti-infective therapies segment is projected to account for 30.1% share in 2025, attributing to critical contribution to the struggle against microbial infections and the increased demand of alternatives to conventional antibiotics. Lysozyme is a naturally found enzyme that has powerful bacteriolytic activity and is being used as an enzyme that is capable of breaking down bacterial cell wall, thus, becoming a potent enzyme against a wide range of pathogens.

Antibiotic resistance has increased across the world, which has led to the increased interest in anti-infective agents that can either be used together with conventional antibiotics or decrease the use of antibiotics, and this has made lysozyme a developing natural antibiotic compound.

Lysozyme Market Insights, By Product Type - Recombinant Lysozyme Dominates Due to Purity, Scalability, and Consistency

Recombinant lysozyme is set to hold 55.6% share in 2025, overcoming limitations of egg whites and animal tissues. This improves access and reduces contamination risks, crucial for pharmaceutical applications.

For example, InVitria launched Lysobac, a recombinant human lysozyme produced in an egg-free system. This high-purity, animal-free enzyme offers four times the activity of egg-based lysozyme and is ideal for bioprocessing, diagnostics, and protein purification. Lysobac is a natural alternative to chemical antibiotics in livestock feed and research applications.

Lysozyme Market Insights, By Form - Lysozyme Solution Leads Due to Its Ease Of Use, Versatility, and Better Bioavailability than Powder Formulations

The Lysozyme solution is expected to capture 65.8% market share in 2025, due to its precise dosing and rapid absorption in therapeutic applications like wound care and antibiotic treatment. Its liquid form ensures homogeneous distribution in pharmaceutical and cosmetic products, delivering consistent therapeutic effects.

Lysozyme solutions are commonly used in both clinical and consumer healthcare products because of their exemplarity to the topical use including sprays, eye drops, and oral rinses. These formats enable direct interaction with affected areas that facilitate rapid antimicrobial effect and healing.

Regulatory & Safety Compliance in the Lysozyme Market

• The lysozyme market is governed by stringent regulatory frameworks that ensure product safety and efficacy, especially for its pharmaceutical and food applications. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require lysozyme to meet specific standards for purity, potency, and quality. For instance, lysozyme used in food preservation must comply with the FDA's food additive regulations, ensuring its safety when consumed. Similarly, lysozyme-based pharmaceutical formulations must meet rigorous safety standards for clinical use, including toxicity assessments and clinical trial approval.
• Examples of Compliance in Practice: Creative Enzymes, a biotechnology firm, ensures compliance with Good Manufacturing Practice (GMP) standards for its recombinant lysozyme products. These products are made under controlled conditions to maintain consistency and quality. In the pharmaceutical industry, lysozyme is regulated for use in drug formulations, such as in treatments for infections and inflammation. For example, when lysozyme is used in wound care or as part of drug delivery systems, it is subject to regulatory scrutiny to guarantee its safe and effective use in patients.

Regional Insights

To learn more about this report, Download Free Sample

North America Lysozyme Market Analysis and Trends

The North America region is projected to lead the market with a 39.3% share in 2025, owing to good pharma-biotech potential, well-developed research infrastructure, and the government policy that promotes innovation. This base makes the region a center of major therapy as well as industrial lysozyme applications.

In North America, companies like Bioseutica and NutriScience Innovations lead the lysozyme market by supplying high-purity lysozyme for pharmaceutical and industrial applications. Medikonda Nutrients and Creative Enzymes also play significant roles in providing lysozyme for immune health and research purposes.

Asia Pacific Lysozyme Market Analysis and Trends

The Asia Pacific region is expected to exhibit the fastest growth in the market contributing 24.6% share in 2025, owing to the booming pharmaceutical and food sectors, growing demand of natural preservatives and awareness concerning health and hygiene. Countries like China, India, and Japan have also issued conducive policies that would encourage biotechnology research and increase the local production capacity.

In India the market is expanding, based on the presence of more biotechnology startups and more investment in agricultural bio-additives. Among other companies like Shanghai Darui Biotechnology in China and Meito Sangyo Co. in Japan are leading the pack in creating innovations that fit the needs of a region.

Lysozyme Market Outlook for Key Countries

U.S. Lysozyme Market Trends

The U.S lysozyme market enjoys robust biotech infrastructures and robust partnerships between the government and the private sector. Such large companies as Danisco and ADM are the leaders in the research and production of high-purity lysozyme used in pharmaceutical, animal nutrition, and food preservation industries. The business environment in the country is conducive in terms of product safety and market introduction of innovative products based on lysozyme. The companies in the U.S are spending heavily on research of new uses of lysozyme in wound care and functional foods, which is enhancing long term leadership in the market.

DuPont Danisco make lysozyme high in purity to be used in the medical field such as anti-inflammatory drugs and drug delivery systems. The company is also making progress in research on lysozyme which is an enzyme based wound care that enhances fast healing and prevention of infection. Neogen Corporation is also investing in the lysozyme solutions to keep the pharmaceutical setting sterile, which is further to boost the healthcare lysozyme market.

China Lysozyme Market Trends

The market for lysozyme in China is fast developing and this has been enhanced by the government efforts aimed at enhancing biotechnological production and sustainable agriculture. The major local competitors such as Shanghai Darui Biotechnology are specializing in the production of cost-effective and high-quality lysozyme to meet the increasing needs in the food preservation industry and animal health industry. Also, robust exportation operations supported by Chinese international trade perspectives make it an essential supplier in the Asia Pacific region. The domestic consumption is also driven by continuous construction of infrastructure and urbanization.

Guangzhou Darui Biotechnology Co., Ltd. is a company that manufactures a respiratory infection and inflammation treatment lysozyme. Jiangsi Boli Bioproducts provides injectable drugs and wound care lysozyme. Beijing Gingko Group plans on lysozyme as an anti-inflammatory drug, which will lead to the development of lysozyme-based therapeutics in the Chinese lysozyme market.

India Lysozyme Market Trends

The market for lysozyme in India is on the rise owing to the rising demand of natural food preservatives and the growth in the investments in biotechnology. The local businesses and startups are undertaking to use the lysozyme in the pharmaceuticals and animal feed with the help of the government schemes that encourage Make in India and biotechnology innovation hubs. The variety of agriculture background and the development of processed food industry bring substantial market player opportunities.

Titan Biotech is a low-cost manufacturer of lysozyme in pharma and nutraceutical markets which is complemented by HiMedia Laboratories that continues to grow the enzyme applications in food and diagnostic markets. Mapro FoodTech contributes to the process of processed foods and preservation applications.

Japan Lysozyme Market Trends

Japan has a strong presence in the market of lysozyme due to its superior pharmaceutical and food technology industries. Established firms like Meito Sangyo Co. are reputed to produce high-quality lysozyme products and it combines the research based on the latest levels and quality assurance. The aging population and the increased demand of health promoting products in the country create the need to innovate on the functional foods and supplements that contain the lysozyme. The trade relations are high in Japan making exportation of lysozyme, particularly in Asia Pacific.

In the pharmaceutical grade of the enzyme, it is Meito Sangyo Co. that is leading and Nagase Group in the development of the advanced ingredients. Amano Enzyme is an enzyme innovation company that is R&D based with enzymes such as lysozyme in functional foods and health products.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Development

• In December 2024, scientists at IASST Guwahati, an autonomous research institute under India’s DST, created lysozyme bilayers on silicon surfaces at room temperature, offering a new way to mimic natural protein adsorption on implants. The team led by Mr. Sarathi Kundu with researchers Mr. Sanu Sarkar and Mrs. Aditi Saikia used sodium, calcium, and yttrium ions to stabilize lysozyme layers, showing how hydrogen bonding, hydrophobic forces, and electrostatic interactions shape protein alignment.

Top Strategies Followed by Global Lysozyme Market Players

• When there are established market leaders, they are likely to spend a lot on research and development (R&D) and therefore they invest a lot in developing high-performance products of lysozyme that match the current standards and customer needs in the industry. Differentiation is reinforced by their emphasis on product innovation which facilitates solution to complex pharmaceutical, food preservation and healthcare requirements. They also increase their market share by having strategic partnerships with OEMs and key players in the industry, which increases their scale and reach.
  • For example, established leaders include DSM, DuPont Danisco, Neova Technologies, Bouwhuis Enthoven, and Kerry Group, all of whom operate large-scale enzyme platforms and supply high-purity lysozyme for pharmaceutical, food, and animal nutrition applications. Their broad manufacturing infrastructure and global customer networks keep them firmly positioned at the high end of the market.

• Middle-tier lysozyme companies are also competing by offering a compromise between cost and product quality to the buyers who are cost-sensitive. Optimization is done by them in the production processes in order to reduce costs, but with satisfactory efficacy and consistency. This strategy will promote competitive prices to appeal to smaller pharmaceutical companies and local food processors.
  • For Example, Mid-level players include Bioseutica, Biosecur Lab, Biovencer Healthcare, Enzybel Group, and Kewpie Corporation, each focusing on cost-optimized extraction or fermentation to offer reliable lysozyme to regional food processors, nutraceutical firms, and mid-tier pharma manufacturers. These companies win through competitive pricing, efficient processes, and steady product quality.

• Small actors in the international lysozyme environment are nimbler and more focused on their specific tasks to compete with bigger firms. They can be differentiated through innovation and customization by focusing on the niche markets or designing special formulations of the lysozyme with special functional properties.
  • For Example, Small-scale innovators include InVitria, Infinita Biotech, Yiming Biological, Jiangsu Baisen Biological, and various emerging recombinant-enzyme startups in China and South Korea that develop application-specific lysozyme variants. Their strength lies in specialized formulations for wound care, microbiome research, precision fermentation, and advanced antimicrobial applications.

Market Report Scope

Lysozyme Market Report Coverage

Lysozyme Market Dynamics

To learn more about this report, Download Free Sample

Lysozyme Market Driver - Rising Antibiotic Resistance

The growing hassle of antibiotic-resistant bacteria in the health care system has been a major challenge to the health care systems all over the globe and this has led to the demand of alternative antimicrobial solutions like lysozyme. Due to the ever-increasing possibilities of using the new compounds, natural compounds that can successfully inhibit the growth of bacteria without the emergence of resistance are becoming a necessity since the effectiveness of conventional antibiotics is gradually declining owing to overuse and genetic resilience against them. Lysozyme is a naturally occurring enzyme that has the power of breaking down the bacterial cell walls, which has become very popular as a bio-preservative and therapeutic agent. Its expansive-spectrum antimicrobial effectiveness, security training, and power to boost immune reaction make it an appealing alternative or addition to the conventional antibiotics.

For Instance, In October 2025, the WHO reported that one in six global infections was resistant to standard antibiotics, with resistance rising over 40% between 2018 and 2023 across monitored pathogen-drug combinations. More than 40% of E. coli and over 55% of K. pneumoniae strains were resistant to third-generation cephalosporins, with levels exceeding 70% in parts of Africa. Surveillance participation grew to 104 countries, yet 48% still failed to report data, and many lacked reliable systems to track antimicrobial resistance.

Lysozyme Market Opportunity - Growth in Recombinant and Engineered Lysozyme Development

The recombinant and engineered lysozyme development is a major growth potential in the global lysozyme market. The traditional lysozymes, mostly obtained by natural sources like egg whites have a limitation in terms of scalability, purity and consistency which can be overcome through the recombinant technology. Genetic engineering and biotechnological tools have made this possible to produce lysozyme variants, which are more antimicrobially active, and stable, and have a wider spectrum of effect on pathogens. These enhancements serve the growing need in pharmaceutical, food preservation, and cosmetic industries where enhanced and accurate bioactive agents have to be used.

A number of companies like Intron Biotechnology, NovaBiotics, Creative Enzymes, Amano Enzyme, Bioseutica and Henan Jindan Lactic Acid Technology are developing recombinant or engineered lysosomes to satisfy these new opportunities.

Analyst Opinion (Expert Opinion)

• The market of lysozyme is expanding due to the adoption being enhanced in the pharmaceutical, food preservation, and animal health segments with the increased use of biotech innovation, stricter food-safety norms, and increased demand of natural antimicrobials. The recombinant and engineered versions are providing access to more purified product form, and there are possibilities in microbiome therapies and pediatric formulations. The industry discussions at BIO International Convention, World Microbiome Forum, and Food Ingredients Europe have intensified convergence on safety, scalability and new application.
• Recent projects on enzyme-engineering and fermentation-based pilots in Europe and Japan are enhancing efficiency of production and stability of supply. Industries are also being pushed to safer biological alternatives through the public health programmes on antimicrobial resistance. The combination of these efforts and the innovation efforts led by the company in the development of lysozyme are producing a market that is becoming more technologically oriented, dependable and prepared to be utilized in a broader clinical and industrial way.

Market Segmentation

• Therapeutic Application Insights (Revenue, USD Mn, 2020 - 2032)
  • Anti-infective Therapies
  • Anti-inflammatory Therapies
  • Gastrointestinal Infection Management
  • Respiratory Infection Management
  • Wound-Healing and Tissue Repair
  • Immunomodulatory Applications
  • Other Therapeutic Uses
• Product Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Recombinant Lysozyme
  • Natural Lysozyme
• Form Insights (Revenue, USD Mn, 2020 - 2032)
  • Lysozyme Solution
  • Lysozyme Powder
• Route of Administration Insights (Revenue, USD Mn, 2020 - 2032)
  • Oral
  • Parenteral
  • Topical
  • Others (Nasal)
• Formulation Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Monotherapies
  • Combination Therapies
• End User Insights (Revenue, USD Mn, 2020 - 2032)
  • Pharmaceutical Manufacturers
  • Biotechnology Companies
  • Hospitals and Clinics
  • Research Institutes
• Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Online
  • Offline
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • dsm-firmenich
  • Bioseutica BV
  • WAKO Chemicals
  • Danish Bioscience
  • Qingdao Vland Biotech
  • Amano Enzyme Inc
  • Lysozyme Corporation
  • Nanning Doing-Higher Bio-Tech
  • Jiangsu Yiming Biological
  • Jiangxi Shineway Pharmaceutical
  • Handary SA
  • Bouwhuis Enthoven
  • AgraFood Ingredients BV
  • Neova Technologies
  • Chr Hansen A/S

Sources

Primary Research Interviews

Industry Stakeholders

• Manufacturing Heads
• R&D Scientists

End Users

• Pharmaceutical Formulators
• Clinical Microbiologists

Government and International Databases

• World Health Organization
• Food and Agriculture Organization
• U.S. Food and Drug Administration
• European Medicines Agency
• UN Comtrade
• Centers for Disease Control and Prevention

Trade Publications

• Chemical & Engineering News
• Food Navigator
• NutraIngredients
• PharmaTimes
• Pharmaceutical Technology
• The Pharma Letter

Academic Journals

• Journal of Applied Microbiology
• International Journal of Biological Macromolecules
• Food Chemistry
• Antimicrobial Agents and Chemotherapy
• Journal of Immunology
• Biotechnology Advances

Reputable Newspapers

• The New York Times
• The Guardian
• Financial Times
• The Wall Street Journal
• Reuters
• The Economic Times

Industry Associations

• International Dairy Federation
• Institute of Food Technologists
• American Society for Microbiology
• European Federation of Biotechnology
• International Association for Food Protection
• Global Organization for EPA and DHA Omega-3s

Public Domain Resources

• ScienceDirect Open Access
• PubMed Central
• National Center for Biotechnology Information
• Directory of Open Access Journals
• OpenAlex

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years